8224 results for "canc*"

in 11.65 milliseconds.

• Single-molecule nanopore sequencing of plasma and cerebrospinal fluid cell-free DNA from paediatric patients with brain and extracranial solid tumours.

  Cell-free DNA (cfDNA) profiling enables minimally invasive cancer detection and monitoring. Here, we report single-molecule nanopore sequencing data generated using the SIMMA assay for 792 plasma and cerebrospinal fluid cfDNA samples from 277 paediatric patients with diverse brain and extracranial tumours. SIMMA is a low-input single-molecule sequencing approach that enables multimodal whole-genome and high-depth targeted sequencing of the same cfDNA sample for both tumour-agnostic and tumour-informed liquid biopsy analysis (Sauer et al. 2026).

  Study EGAS50000001839

• Detection of high-grade serous ovarian cancer using TP53 mutation burden in uterine lavage

  In total, 436 DNA samples from the 278 patients were processed for TP53 ultradeep duplex sequencing: 278 lavages, 86 tissue samples (some patients had multiple tissue samples), and 72 blood samples. Duplex sequencing was performed on an Illumina NovaSeq 6000 by TwinStrand Biosciences using a capture panel targeting the coding regions of the TP53 gene. Data were processed by TwinStrand Biosciences and .bam files were created for each sample.

  Dataset EGAD50000002776

• Single-cell RNA sequencing of liver metastasis-derived colorectal cancer organoids profiling cellular heterogeneity and lineage dynamics across time

  The objective of this analysis was to identify, at single-cell resolution, trasncriptionally distinct subpopulations in untreated metastatic colorectal cancer organoids with diverse genetic backgrounds and to investigate their temporal dynamics.

  Study EGAS50000001927

• Transcriptome profiling of liver metastasis-derived colorectal cancer organoids to dissect pro-differentiative effects of TGFB1 and IL-6

  Bulk RNA sequencing was performed on patient-derived xenograft (PDX)-derived organoid models of metastatic colorectal cancer (mCRC). The aim of this study was to test the effect of IL-6 and TGFbeta1 on mCRC organoid cell differentiation. Transcriptomic profiling was conducted following cytokine treatments to investigate molecular changes associated with treatments. Three biological replicates were included for each experimental condition (control, IL-6, and TGF-beta1 treatments).

  Study EGAS50000001914

• Bulk RNA sequencing of metastatic colorectal cancer PDX-derived organoids - untreated and treated with IL-6 or TGF-beta1

  Bulk RNA sequencing was performed on patient-derived xenograft (PDX)-derived organoid models of metastatic colorectal cancer (mCRC). The aim of this study was to test the effect of IL-6 and TGF-beta1 on mCRC organoid cell differentiation. Transcriptomic profiling was conducted following cytokine treatments to investigate molecular changes associated with treatments.

  Dataset EGAD50000002782

• Single-cell transcriptomic profiling of metastatic colorectal cancer organoids maintained in growth medium.

  Single-cell RNA sequencing was performed on metastatic colorectal cancer (mCRC) organoids derived from patient-derived xenograft (PDX) models. Organoids were seeded in 12-well plates, embedded in 200 µL of Matrigel or BME diluted 1:1 with culture medium, and maintained with EGF-supplemented growth medium. After 7 days (or 11 days) of growth, organoids were harvested, dissociated, and live single cells were sorted for single-cell RNA sequencing using the 10x Genomics platform.

  Dataset EGAD50000002797

• IRCCS Candiolo - Quantitative Cancer Cell Biology (QCCB)

  DAC for Quantitative Cancer Cell Biology (QCCB) datasets

  Dac EGAC50000001019

• Personalized ctDNA detection and genomic profiling in the NeoRHEA Study

  In the management of early hormone receptor (HR)+, HER2-negative breast cancer, circulating tumor DNA (ctDNA) detection is an evolving yet promising diagnostic approach. We evaluated ctDNA detection using the personalized RaDaR assay in plasma samples from patients enrolled in the NeoRHEA clinical trial (NCT03065621), a single-arm, phase II study of neoadjuvant palbociclib and endocrine therapy administered over 4 months (four 28‑day cycles). Plasma samples were collected pre-treatment, after the first treatment cycle, prior to surgery, and one month post-surgery. At baseline, ctDNA positivity was detected in 55% of patients; however, this dropped to 5% during treatment and ctDNA became undetectable in all patients by one month post-surgery. CtDNA detection at baseline was higher in histological grade 3 tumors, lower in multifocal/multicentric tumors and higher in residual cancer burden (RCB) 3 tumors. Genomic analysis revealed MYC gene gains or amplifications were more frequent in ultrasound (US) responders, while PIK3CA gains were more common in US non-responders. Additionally, FAT1 losses were more frequently observed in patients with RCB 3. Our findings suggest that baseline ctDNA presence predicts poor response to neoadjuvant palbociclib and endocrine therapy, underscoring its potential as a biomarker to guide tailored therapeutic approaches in HR+/HER2-negative breast cancer.

  Study EGAS50000001702

• Personalized ctDNA Monitoring and Matched Tumor–Normal Whole-Exome Sequencing in Early HR+/HER2− Breast Cancer

  The dataset comprises whole-exome sequencing (WES) data generated from 160 samples, corresponding to matched tumor–normal pairs from breast cancer patients. For each subject, one tumor biopsy sample and one matched white blood cell (WBC) sample (germline control) are included. Sequencing data are provided as aligned BAM files with corresponding BAI index files. The data were generated using Illumina paired-end sequencing technology following hybrid-capture exome enrichment. The matched tumor–normal design enables accurate identification of somatic variants by filtering germline alterations, supporting downstream analyses such as mutation profiling, biomarker discovery, and personalized circulating tumor DNA (ctDNA) assay development.

  Dataset EGAD50000002446

• Plasma CTCF ChIP-seq Reveals Cancer-Associated cfDNA Binding Profiles

  Cell-free DNA (cfDNA) in plasma predominantly exists as nucleoprotein complexes. Although circulating CTCF-bound cfDNA (cfCTCF-DNA) has previously been reported, the occupancy of individual CTCF binding sites in plasma has not been systematically characterised. This study describes the isolation of endogenous plasma cfCTCF-DNA by chromatin immunoprecipitation followed by next-generation sequencing (ChIP-seq) in samples obtained from cancer patients and healthy individuals. A two-step enrichment strategy was employed, combining physical removal of background cfDNA by immunoprecipitation with bioinformatic filtering to remove residual non-CTCF-derived sequences. Sequencing reads were aligned to the UCSC hg38 reference genome using BWA-MEM v0.7.17 and processed to generate CRAM files containing alignments restricted to the primary chromosomes (chr1–chr22, chrX, chrY and chrM). CTCF-associated cfDNA fragments were classified according to their similarity to a consensus CTCF binding motif, enabling discrimination between low-affinity and high-affinity CTCF binding sites. Comparative analyses identified quantitative and qualitative differences in plasma cfCTCF-DNA profiles between healthy individuals and patients with cancer. The deposited dataset comprises plasma cfCTCF-DNA ChIP-seq data from four clinical cohorts and includes both CTCF-enriched and total cfDNA samples where applicable. These data support the investigation of CTCF occupancy patterns as a novel class of liquid biopsy biomarkers for cancer detection and monitoring.

  Study EGAS50000001937